ConductScience.org, home

Paper32099495

Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.

Inoue H and 1 other. Lung Cancer (Auckl), 2019. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives. Papers, record 32099495. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32099495

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.
PubMed
Journal
Lung Cancer (Auckl)
PubMed
Year
2019
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
0.44
iCite
Revised in PubMed
2020-09-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Inoue HHiroyuki
2Okamoto IIsamu

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120530281
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
J Clin Oncol2010https://conductscience.org/library/papers/20530281PubMed
227932443PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.EMBO Mol Med2017https://conductscience.org/library/papers/27932443PubMed
326712084Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.Lancet2016https://conductscience.org/library/papers/26712084PubMed
48011301Tolerance, danger, and the extended family.Annu Rev Immunol1994https://conductscience.org/library/papers/8011301PubMed
527565935Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.Lung Cancer2016https://conductscience.org/library/papers/27565935PubMed
627979383Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Lancet2017https://conductscience.org/library/papers/27979383PubMed
724382348Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.J Clin Invest2014https://conductscience.org/library/papers/24382348PubMed
830280658Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.N Engl J Med2018https://conductscience.org/library/papers/30280658PubMed
927468145PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.Eur J Cancer2016https://conductscience.org/library/papers/27468145PubMed
1025274032Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.Cancer Res2014https://conductscience.org/library/papers/25274032PubMed
1124331154Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.Lancet Oncol2014https://conductscience.org/library/papers/24331154PubMed
1225601342
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Lancet Oncol2015https://conductscience.org/library/papers/25601342PubMed
1328885881Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med2017https://conductscience.org/library/papers/28885881PubMed
1425754814Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity.Cancer Lett2015https://conductscience.org/library/papers/25754814PubMed
1530320184Immunogenic effects of chemotherapy-induced tumor cell death.Genes Dis2018https://conductscience.org/library/papers/30320184PubMed
1612493003Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease.Immunol Rev2002https://conductscience.org/library/papers/12493003PubMed
1725534129A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.Lung Cancer2015https://conductscience.org/library/papers/25534129PubMed
1823832118Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.Cell Death Differ2014https://conductscience.org/library/papers/23832118PubMed
1926811519
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
J Clin Oncol2016https://conductscience.org/library/papers/26811519PubMed
2025481261Radiotherapy and immunogenic cell death.Semin Radiat Oncol2015https://conductscience.org/library/papers/25481261PubMed

See all 48 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
40400937Expert consensus on cancer treatment-related lung injury.J Thorac Dis2025https://conductscience.org/library/papers/40400937PubMed
38203731Non-Coding RNAs as Key Regulators in Lung Cancer.Int J Mol Sci2023https://conductscience.org/library/papers/38203731PubMed
37781162Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis.EClinicalMedicine2023https://conductscience.org/library/papers/37781162PubMed
35967142The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression.Cureus2022https://conductscience.org/library/papers/35967142PubMed
35330063Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment.J Clin Med2022https://conductscience.org/library/papers/35330063PubMed
33860055Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.Biomed Res Int2021https://conductscience.org/library/papers/33860055PubMed
33628725Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients.Front Oncol2020https://conductscience.org/library/papers/33628725PubMed
32833338
Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
Thorac Cancer2020https://conductscience.org/library/papers/32833338PubMed
32513983Circular RNA circSLC25A16 contributes to the glycolysis of non-small-cell lung cancer through epigenetic modification.Cell Death Dis2020https://conductscience.org/library/papers/32513983PubMed

Download CSV of cited by

Genes27

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AGER177PubTator's text mininghttps://conductscience.org/library/genes/177NCBI Gene
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CALR811PubTator's text mininghttps://conductscience.org/library/genes/811NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD80941PubTator's text mininghttps://conductscience.org/library/genes/941NCBI Gene
CD86942PubTator's text mininghttps://conductscience.org/library/genes/942NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
HLA-C3107PubTator's text mininghttps://conductscience.org/library/genes/3107NCBI Gene
HMGB13146PubTator's text mininghttps://conductscience.org/library/genes/3146NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL103586PubTator's text mininghttps://conductscience.org/library/genes/3586NCBI Gene
LRP14035PubTator's text mininghttps://conductscience.org/library/genes/4035NCBI Gene
MLKL197259PubTator's text mininghttps://conductscience.org/library/genes/197259NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
RIPK311035PubTator's text mininghttps://conductscience.org/library/genes/11035NCBI Gene

See all 27 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32099495

GET https://conductscience.org/api/papers/v1/32099495/references?page=2